Value through Innovation30 June 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation


2014: Boehringer Ingelheim positioned for future growth with product launches


New international survey of lung cancer oncologists highlights underutilization of personalized treatments

- For media outside the US, the UK and Canada only

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders


Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union

- For media outside the US, the UK and Canada only

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study


- For Non-UK / Non-Canadian Media only

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

- For Non-US/Non-UK/Non-Canadian Media

EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe


Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

- For Non-US/Non-UK Media

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe


Boehringer Ingelheim Animal Health continues support of independent PCV2 research


New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD

- For media outside the US, the UK and Canada

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

- For media outside UK, US and Canada

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals


35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia


Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment


Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas


The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

- For media outside UK, US and Canada only